Table 2.
Age-adjusted and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer (BC)-specific death according to race and tumor characteristics among non-Hispanic White (NHW) and non-Hispanic Black (NHB) women diagnosed with BC in the metropolitan Atlanta area 2010–2014 and registered with the Georgia Cancer Registry
| Characteristic | No. deaths |
Common referent HR (95% CI) |
RERI (95% CI) | Stratified effects | Stratified effects* | ||
|---|---|---|---|---|---|---|---|
| NHW | NHB | NHW | NHB | HR (95% CI) | HR (95% CI) | ||
| Stage | |||||||
| I | 31 | 29 | Referent | 1.97 (1.19 to 3.26) | — | 2.08 (1.26 to 3.43) | 1.13 (0.63 to 2.01) |
| II | 80 | 118 | 4.75 (3.13 to 7.21) | 8.96 (6.02 to 13.35) | 3.25 (1.01 to 5.49) | 1.89 (1.41 to 2.53) | 1.42 (1.04 to 1.95) |
| III | 85 | 126 | 18.85 (12.43 to 28.59) | 29.97 (20.14 to 44.61) | 10.16 (2.52 to 17.79) | 1.57 (1.17 to 2.09) | 1.24 (0.90 to 1.71) |
| IV | 123 | 215 | 69.59 (46.43 to 104.3) | 127.7 (87.01 to 187.4) | 57.13 (26.5 to 87.75) | 1.73 (1.34 to 2.22) | 1.57 (1.19 to 2.06) |
| P Interaction | .81 | .47 | |||||
| Grade | |||||||
| 1 | 20 | 14 | Referent | 1.92 (0.96 to 3.87) | — | 1.99 (0.98 to 4.03) | 1.74 (0.70 to 4.29) |
| 2 | 97 | 119 | 3.02 (1.86 to 4.91) | 6.54 (4.06 to 10.53) | 2.59 (0.73 to 4.46) | 2.21 (1.67 to 2.92) | 1.72 (1.26 to 2.35) |
| 3+ | 154 | 286 | 8.24 (5.16 to 13.16) | 14.43 (9.15 to 22.76) | 5.26 (2.18 to 8.34) | 1.71 (1.40 to 2.10) | 1.14 (0.92 to 1.42) |
| P Interaction | .38 | .06 | |||||
| ER status | |||||||
| ER+ | 209 | 282 | Referent | 2.45 (2.03 to 2.95) | — | 2.49 (2.07 to 2.99) | 1.62 (1.31 to 2.00) |
| ER- | 90 | 189 | 3.37 (2.61 to 4.34) | 5.32 (4.34 to 6.52) | 0.51 (−0.58 to 1.59) | 1.57 (1.21 to 2.02) | 1.15 (0.86 to 1.53) |
| P Interaction | .007 | .08 | |||||
| Molecular subtype | |||||||
| Luminal A | 171 | 221 | Referent | 2.42 (1.98 to 2.95) | — | 2.43 (1.99 to 2.97) | 1.58 (1.25 to 1.98) |
| Luminal B | 31 | 56 | 1.37 ( 0.93 to 2.01) | 3.26 (2.40 to 4.43) | 0.48 (−0.56 to 1.52) | 2.57 (1.66 to 3.98) | 1.53 (0.96 to 2.45) |
| HER2 overexpressing | 16 | 40 | 2.29 (1.37 to 3.83) | 5.59 (3.96 to 7.91) | 1.88 (−0.21 to 3.98) | 2.51 (1.41 to 4.46) | 1.69 (0.87 to 3.30) |
| TNBC | 65 | 137 | 3.92 (2.94 to 5.22) | 5.46 (4.35 to 6.85) | 0.12 (−1.24 to 1.49) | 1.36 (1.01 to 1.82) | 1.09 (0.78 to 1.53) |
| P Interaction | .02 | .16 | |||||
*
Adjusted for age; stage; subtype; receipt of surgery, chemotherapy, radiation, hormone therapy, and trastuzumab; insurance status. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; RERI = relative excess risk due to interaction; TNBC = triple-negative BC.